These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 1308966)

  • 41. [Clinical study of ofloxacin in complicated urinary tract infection].
    Akazawa N; Tsugawa M; Hayata S; Sasaki H; Asahi T; Okita K
    Hinyokika Kiyo; 1988 Jul; 34(7):1279-82. PubMed ID: 3177148
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibiotic resistance in children with recurrent or complicated urinary tract infection.
    Younis N; Quol K; Al-Momani T; Al-Awaisheh F; Al-Kayed D
    JNMA J Nepal Med Assoc; 2009; 48(173):14-9. PubMed ID: 19529052
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Rational antibiotic therapy of urinary tract infections].
    Wagenlehner FM; Naber KG; Weidner W
    Med Monatsschr Pharm; 2008 Oct; 31(10):385-90; quiz 391-2. PubMed ID: 18972869
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical experience with cefmetazole in the urological field].
    Aga Y; Yano M; Ogura K
    Hinyokika Kiyo; 1983 Apr; 29(4):459-63. PubMed ID: 6587763
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Single-dose enoxacin compared with 3-day treatment for urinary tract infection.
    Backhouse CI; Matthews JA
    Antimicrob Agents Chemother; 1989 Jun; 33(6):877-80. PubMed ID: 2764538
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enoxacin--a new fluoroquinolone.
    Med Lett Drugs Ther; 1992 Nov; 34(883):103-5. PubMed ID: 1435504
    [No Abstract]   [Full Text] [Related]  

  • 47. [Clinical experience of norfloxacin (Baccidal) in the urological field].
    Fukuoka H; Goto A; Sasaki S
    Hinyokika Kiyo; 1985 Sep; 31(9):1667-74. PubMed ID: 4083223
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Double-blind comparative clinical study of cefpiramide (SM-1652) and cefsulodin on complicated urinary tract infections due to P. aeruginosa].
    Kawamura N; Ohkoshi M; Okada K; Kumamoto Y; Miyamoto S; Niijima T; Kishi Y; Nishimura Y; Saito I; Yuge J
    Hinyokika Kiyo; 1983 Sep; 29(9):1147-88. PubMed ID: 6375316
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enoxacin relieves symptoms of recurrent urinary infections more rapidly than cefuroxime axetil.
    Brumfitt W; Hamilton-Miller JM; Walker S
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1558-9. PubMed ID: 8363392
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.
    Patel SS; Spencer CM
    Drugs; 1996 Jan; 51(1):137-60. PubMed ID: 8741236
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Henwood JM; Monk JP
    Drugs; 1988 Jul; 36(1):32-66. PubMed ID: 3063494
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tissue penetration and clinical efficacy of enoxacin in urinary tract infections.
    Childs SJ
    Clin Pharmacokinet; 1989; 16 Suppl 1():32-7. PubMed ID: 2653693
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An open study of the safety and efficacy of enoxacin in complicated urinary tract infections.
    Foot M; Williams G; Want S; Roe M; Quaghebeur G; Bates S
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():97-103. PubMed ID: 3129393
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect on urogenital flora of antibiotic therapy for urinary tract infection.
    Reid G; Bruce AW; Cook RL; Llano M
    Scand J Infect Dis; 1990; 22(1):43-7. PubMed ID: 2181630
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enoxacin in the treatment of complicated urinary tract infections.
    Roe CJ; Becker GJ; Whitworth JA; Kincaid-Smith P
    Aust N Z J Med; 1987 Feb; 17(1):81-2. PubMed ID: 3304243
    [No Abstract]   [Full Text] [Related]  

  • 56. Prevention of subsequent urinary tract infections in women by the use of anti-adherence antimicrobial agents: a double-blind comparison of enoxacin with co-trimoxazole.
    Donabedian H; O'Donnell E; Drill C; Lipton LM; Khuder SA; Burnham JC
    J Antimicrob Chemother; 1995 Mar; 35(3):409-20. PubMed ID: 7782257
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enoxacin treatment of urinary tract infections.
    Thomas MG; Ellis-Pegler RB
    J Antimicrob Chemother; 1985 Jun; 15(6):759-63. PubMed ID: 3861605
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enoxacin treatment of urinary tract infections in elderly patients.
    Huttunen M; Kunnas K; Saloranta P
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():105-11. PubMed ID: 3162900
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Efficacy and tolerance of Uroflux, a bladder and kidney tea, in the treatment of urinary tract infections, especially in diabetes mellitus].
    Steger W; Haase W
    Fortschr Med; 1979 Nov; 97(43):2007-10. PubMed ID: 574483
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections.
    Marchbanks CR; Mikolich DJ; Mayer KH; Zinner SH; Dudley MN
    Antimicrob Agents Chemother; 1990 Oct; 34(10):1966-72. PubMed ID: 2291662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.